Breezula sold at Anagen Inc & Universal Labs - has anyone tried it? 1/16/2026
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity Why is everyone still arguing about PP405 when clascoterone is already heading toward regulatory submission?
Clascoterone is nearing regulatory submission as a potential new treatment for androgenetic alopecia, with positive Phase III results, while discussions continue about other treatments like PP405, minoxidil, and finasteride. Some users express excitement for clascoterone and Breezula, despite concerns about the effectiveness and practicality of topical treatments.
community Clascoterone for hair loss. Promising study.
A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
community Is this sub gonna accept that PP405 is a nothingburger? Or do we wait 5 more years?
The conversation discusses skepticism about the effectiveness of PP405 for hair loss, with users mentioning treatments like dutasteride, oral minoxidil, clascoterone, and upcoming drugs like breezula and long-release oral minoxidil. Some users express hope for future treatments like vdphl01 and amplifica, while others debate the effectiveness and side effects of current options.
community Clascoterone/ Breezula will it work
Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.
community Are these new hair loss treatments ever gonna release?
Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.
community When will Breezula be released and how does it compare to KX-826?
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
Related Research
6 / 6 resultsresearch Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Recent Advances in Drug Development for Hair Loss
This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
research 0951 Breezula, a clinical stage topical anti-androgen, promotes dermal papilla inductivity and reduces IL-6 secretion in balding skin samples ex vivo
This study suggests that Breezula® and Minoxidil both enhance hair growth in male pattern hair loss by promoting keratinocyte proliferation, with Breezula® potentially more potent in reducing the hair growth inhibitor IL-6.
research Androgenetic Alopecia: An Update of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
research New drugs under investigation for the treatment of alopecias
This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.
research Androgenetic alopecia: combing the hair follicle signaling pathways for new therapeutic targets and more effective treatment options
This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.